查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1908606

乳癌診斷市場規模、佔有率和趨勢分析報告：按類型、產品、應用、最終用途、地區和細分市場預測（2026-2033 年）

Breast Cancer Diagnostics Market Size, Share & Trends Analysis Report By Type (Imaging, Biopsy, Genomic Tests, Blood Tests), By Product (Platform-based, Instrument-based), By Application, By End Use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10個工作天內

價格

乳癌診斷市場概覽

全球乳癌診斷市場預計到 2025 年價值 58.6 億美元，預計到 2033 年將達到 113.6 億美元。

預計從 2026 年到 2033 年，其複合年成長率將達到 8.8%。這一成長可歸因於癌症發生率的上升以及政府為提高篩檢和診斷率而加強的力度。

乳癌發生率的上升預計將推動乳癌診斷市場的發展。根據美國癌症協會（ACS）發布的《2024年乳癌事實與數據》，乳癌仍然是美國女性最常見的癌症。預計2024年將新增310,720例侵襲性乳癌病例和55,720例乳管原位癌（DCIS）病例。

多種因素導致乳癌發生率上升，包括年齡成長、生活方式改變、遺傳易感性和環境因素。隨著預期壽命的延長，越來越多的女性進入乳癌高風險年齡層。此外，肥胖、缺乏運動、荷爾蒙療法乳癌乳癌的需求。雖然乳房X光攝影仍然是乳癌篩檢的黃金標準，但數位乳房斷層合成（DBT）、造影乳房X光乳房X光攝影、超音波、磁振造影（MRI）和分子診斷檢測技術的進步推動了市場成長。人工智慧（AI）在影像學中的應用進一步提高了早期檢測能力，提高了準確性，並減少了假陽性和假陰性結果。此外，液態生物檢體和基於生物標記的診斷方法已成為檢測乳癌和監測治療效果的非侵入性工具。

為了應對日益嚴重的乳癌負擔，全球醫療衛生系統加大了對乳癌篩檢計畫的投入。各國政府和私人醫療機構擴大了診斷服務的覆蓋範圍，尤其是在篩檢率歷來較低的發展中地區。對早期檢測和個人化醫療的重視加速了新一代定序（NGS）、基因檢測和伴隨診斷技術的普及應用。隨著乳癌發病率的持續上升，乳癌診斷市場也經歷了持續成長。技術的不斷進步，加上公眾意識的提高和篩檢服務的普及，推動了對能夠實現更早期、更精準癌症檢測的創新診斷解決方案的需求。

擴大乳癌篩檢的報銷範圍和保險覆蓋率預計將推動市場成長。世界各地的政府機構，例如德國聯邦聯合委員會，已核准該檢測納入全國報銷範圍。在美國，醫療補助計劃 (Medicaid)、醫療保險計劃 (Medicare) 和第三方支付機構的福利計劃涵蓋乳癌基因檢測的費用，包括 BRCA1 和 BRCA2 基因檢測，而且全球範圍內進行的檢測數量正在增加。此外，醫療保險 B 部分 (Medicare Part B) 為 40 歲及以上的女性報銷每年一次乳房 X 光檢查數位乳房攝影檢查 80% 的費用。

此外，Agendia於2025年2月宣布，布魯塞爾國家疾病與意外保險研究所（INAMI-RIZIV）已擴大MammaPrint的承保範圍，將其用於新輔助化療。自2025年1月1日起，這意味著HR+/HER2陰性早期乳癌患者將獲得全額報銷，並可透過核心針穿刺活體組織切片進行基因組檢測，以指南新輔助治療方案的發展。此次承保範圍的擴大標誌著在為患者提供更個人化的治療方面邁出了重要一步。布魯塞爾自由大學腫瘤學榮譽教授Martine Picart教授就此進展的影響評論道：「MammaPrint在比利時應用於核心針穿刺活體組織切片樣本是乳癌個性化治療的一個重要里程碑。新輔助化療的益處巨大，而MammaPrint尤其能夠幫助醫生更精準地制定治療方案，如果選擇合適的治療方案，則有可能小規模手術次數。」

目錄

第1章調查方法和範圍

第2章執行摘要

第3章 市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關及附隨市場展望
  • 市場趨勢與展望
  • 市場動態
  • 商業環境分析
    • PESTLE分析
    • 波特五力分析
  • 新冠疫情影響分析

第4章 按類型進行業務分析

  • 乳癌診斷市場：類型差異分析，2025 年和 2033 年
  • 影像
  • 切片檢查
  • 基因組檢測
  • 血液檢查
  • 其他

第5章：依產品進行業務分析

  • 乳癌診斷市場：產品差異分析（2025 年和 2033 年）
  • 基於平台的產品
  • 設備類產品

第6章：按應用程式進行業務分析

  • 乳癌診斷市場：應用趨勢分析（2025 年和 2033 年）
  • 篩檢
  • 診斷與預測
  • 預後診斷
  • 研究

第7章 依最終用途進行業務分析

  • 乳癌診斷市場：按最終用途分類的變化分析（2025 年和 2033 年）
  • 醫院和診所
  • 醫學檢查室/診斷中心
  • 其他

第8章：區域商業分析

  • 區域市場概覽
  • 北美洲
    • 2021-2033年北美乳癌診斷市場
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 2021-2033年歐洲乳癌診斷市場
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 2021-2033年亞太地區乳癌診斷市場
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 2021-2033年拉丁美洲乳癌診斷市場
    • 主要國家的趨勢
    • 法律規範
    • 競爭場景
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 2021-2033年中東及非洲乳癌診斷市場
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭情勢

  • 公司分類
  • 策略規劃
    • 獲得
    • 合夥
    • 新平台推出
    • 其他
  • 公司簡介/上市資訊
    • Hologic Inc.
    • Genomic Health（Exact Sciences Corporation）
    • BD
    • Danaher
    • Koninklijke Philips NV
    • QIAGEN
    • Thermo Fisher Scientific Inc
    • Myriad Genetics
    • Argon Medical Devices, Inc.
    • F. Hoffmann-La Roche Ltd.
Product Code: GVR-3-68038-694-3

Breast Cancer Diagnostics Market Summary

The global breast cancer diagnostics market size was estimated at USD 5.86 billion in 2025, and is projected to reach USD 11.36 billion by 2033, growing at a CAGR of 8.8% from 2026 to 2033. The growth can be attributed to the increasing prevalence of cancer and rising government initiatives to increase the screening and diagnostic rates.

The increasing incidence of breast cancer is expected to drive the breast cancer diagnostics market. According to the American Cancer Society's Breast Cancer Facts & Figures 2024, breast cancer remained the most commonly diagnosed cancer among women in the U.S. In 2024, an estimated 310,720 new cases of invasive breast cancer were expected to be diagnosed, along with 55,720 cases of ductal carcinoma in situ (DCIS).

Several factors contributed to the increasing incidence of breast cancer, including aging populations, lifestyle changes, genetic predisposition, and environmental influences. As life expectancy increased, more women reached ages where breast cancer risk was higher. In addition, risk factors such as obesity, sedentary lifestyles, hormonal therapies, and delayed childbearing were linked to a greater likelihood of developing breast cancer. Increased awareness and improved screening programs also led to a rise in reported cases, as more cancers were detected at earlier stages. With the growing number of breast cancer cases, the need for effective and accurate diagnostic technologies. Mammography remained the gold standard for breast cancer screening, but advancements in digital breast tomosynthesis (DBT), contrast-enhanced mammography, ultrasound, MRI, and molecular diagnostic tests drove market growth. The integration of AI in imaging interpretation further improved early detection capabilities, enhancing accuracy while reducing false positives and negatives. In addition, liquid biopsy and biomarker-based diagnostics emerged as non-invasive tools for detecting breast cancer and monitoring treatment response.

Healthcare systems worldwide have increased investments in breast cancer screening programs to address the rising burden. Governments and private healthcare providers expanded access to diagnostic services, particularly in developing regions where screening rates had historically been lower. The focus on early detection and personalized medicine accelerated the adoption of next-generation sequencing (NGS), genetic testing, and companion diagnostics. As breast cancer incidence continued to rise, the breast cancer diagnostics market experienced sustained growth. Ongoing advancements in technology, combined with greater awareness and improved accessibility to screening, drove demand for innovative diagnostic solutions that enabled earlier and more accurate cancer detection.

The increasing reimbursement and insurance coverage for breast cancer testing is anticipated to drive market growth. Government agencies in various countries, such as the German Federal Joint Committee, have approved tests for nationwide reimbursement. In the U.S., Medicaid, Medicare, and third-party payer benefit plans cover the cost of breast cancer genetic testing, including BRCA1 and BRCA2 tests, increasing the number of procedures conducted globally. Furthermore, Medicare Part B covers 80% of the cost of one mammogram and digital mammogram screening per year for women aged 40 and older.

Moreover, In February 2025, Agendia, Inc. announced that the National Institute for Sickness and Invalidity Insurance (INAMI-RIZIV) in Brussels has expanded the reimbursement criteria for MammaPrint, now covering its use in the neoadjuvant setting. Effective January 1, 2025, this decision allows full reimbursement for patients with HR+/HER2-negative early-stage breast cancer, enabling genomic testing on core needle biopsies to guide neoadjuvant treatment decisions. This expansion marks a significant step forward in providing patients with more personalized care. Professor Martine Piccart, Honorary Professor of Oncology at the Universite Libre de Bruxelles, highlighted the impact of this advancement, stating, "The ability to use MammaPrint on core needle biopsy specimens in Belgium represents a major milestone for personalized breast cancer treatment. The benefits of neoadjuvant therapy are substantial, especially when guided by MammaPrint, as it enables physicians to tailor treatment plans more precisely. This can lead to less extensive surgical procedures when the appropriate treatment is selected."

Global Breast Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021-2033. For this report, Grand View Research has segmented the breast cancer diagnostics market by type, product, application end use, and region.

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Imaging
  • Biopsy
  • Genomic Tests
  • Blood Tests
  • Others
  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Platform-based products
    • Next Generation Sequencing
    • Microarrays
    • PCR
    • Others
  • Instrument-based products
    • Imaging
    • Biopsy
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Screening
  • Diagnostic & Predictive
  • Prognostic
  • Research
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals & Clinics
  • Medical labs & Diagnostics Centers
  • Others
  • Region Outlook (Revenue, USD Million, 2021-2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Market Definitions
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Type and Product Snapshot
  • 2.3. Application and End Use Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
    • 3.3.2. Market Restraint Analysis
  • 3.4. Business Environment Analysis
    • 3.4.1. PESTLE Analysis
    • 3.4.2. Porter's Five Forces Analysis
  • 3.5. COVID-19 Impact Analysis

Chapter 4. Type Business Analysis

  • 4.1. Breast Cancer Diagnostics Market: Type Movement Analysis, 2025 & 2033
  • 4.2. Imaging
    • 4.2.1. Imaging Market, 2021 - 2033 (USD Million)
  • 4.3. Biopsy
    • 4.3.1. Biopsy Market, 2021 - 2033 (USD Million)
  • 4.4. Genomic Tests
    • 4.4.1. Genomic Tests Market, 2021 - 2033 (USD Million)
  • 4.5. Blood Tests
    • 4.5.1. Blood Tests Market, 2021 - 2033 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Product Business Analysis

  • 5.1. Breast Cancer Diagnostics Market: Product Movement Analysis, 2025 & 2033
  • 5.2. Platform-based products
    • 5.2.1. Platform-based Products Market, 2021 - 2033 (USD Million)
  • 5.3. Instrument-based products
    • 5.3.1. Instrument-based Products Market, 2021 - 2033 (USD Million)

Chapter 6. Application Business Analysis

  • 6.1. Breast Cancer Diagnostics Market: Application Movement Analysis, 2025 & 2033
  • 6.2. Screening
    • 6.2.1. Screening Market, 2021 - 2033 (USD Million)
  • 6.3. Diagnostic & Predictive
    • 6.3.1. Diagnostic & Predictive Market, 2021 - 2033 (USD Million)
  • 6.4. Prognostic
    • 6.4.1. Prognostic Market, 2021 - 2033 (USD Million)
  • 6.5. Research
    • 6.5.1. Research Market, 2021 - 2033 (USD Million)

Chapter 7. End Use Business Analysis

  • 7.1. Breast Cancer Diagnostics Market: End Use Movement Analysis, 2025 & 2033
  • 7.2. Hospitals & Clinics
    • 7.2.1. Hospitals & Clinics Market, 2021 - 2033 (USD Million)
  • 7.3. Medical labs & Diagnostics Centers
    • 7.3.1. Medical labs & Diagnostics Centers Market, 2021 - 2033 (USD Million)
  • 7.4. Others
    • 7.4.1. Others Market, 2021 - 2033 (USD Million)

Chapter 8. Regional Business Analysis

  • 8.1. Regional Market Snapshot
  • 8.2. North America
    • 8.2.1. North America Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. U.S. Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.2.2.2. Key Country Dynamics
      • 8.2.2.3. Regulatory Framework
      • 8.2.2.4. Competitive Scenario
    • 8.2.3. Canada
      • 8.2.3.1. Canada Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.2.3.2. Key Country Dynamics
      • 8.2.3.3. Regulatory Framework
      • 8.2.3.4. Competitive Scenario
    • 8.2.4. Mexico
      • 8.2.4.1. Mexico Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.2.4.2. Key Country Dynamics
      • 8.2.4.3. Regulatory Framework
      • 8.2.4.4. Competitive Scenario
  • 8.3. Europe
    • 8.3.1. Europe Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.2. Germany
      • 8.3.2.1. Germany Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.2.2. Key Country Dynamics
      • 8.3.2.3. Regulatory Framework
      • 8.3.2.4. Competitive Scenario
    • 8.3.3. UK
      • 8.3.3.1. UK Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.3.2. Key Country Dynamics
      • 8.3.3.3. Regulatory Framework
      • 8.3.3.4. Competitive Scenario
    • 8.3.4. France
      • 8.3.4.1. France Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.4.2. Key Country Dynamics
      • 8.3.4.3. Regulatory Framework
      • 8.3.4.4. Competitive Scenario
    • 8.3.5. Italy
      • 8.3.5.1. Italy Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.5.2. Key Country Dynamics
      • 8.3.5.3. Regulatory Framework
      • 8.3.5.4. Competitive Scenario
    • 8.3.6. Spain
      • 8.3.6.1. Spain Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.6.2. Key Country Dynamics
      • 8.3.6.3. Regulatory Framework
      • 8.3.6.4. Competitive Scenario
    • 8.3.7. Denmark
      • 8.3.7.1. Denmark Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.7.2. Key Country Dynamics
      • 8.3.7.3. Regulatory Framework
      • 8.3.7.4. Competitive Scenario
    • 8.3.8. Sweden
      • 8.3.8.1. Sweden Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.8.2. Key Country Dynamics
      • 8.3.8.3. Regulatory Framework
      • 8.3.8.4. Competitive Scenario
    • 8.3.9. Norway
      • 8.3.9.1. Norway Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.9.2. Key Country Dynamics
      • 8.3.9.3. Regulatory Framework
      • 8.3.9.4. Competitive Scenario
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Japan Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.2.2. Key Country Dynamics
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Competitive Scenario
    • 8.4.3. China
      • 8.4.3.1. China Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.3.2. Key Country Dynamics
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Competitive Scenario
    • 8.4.4. India
      • 8.4.4.1. India Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.4.2. Key Country Dynamics
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Competitive Scenario
    • 8.4.5. South Korea
      • 8.4.5.1. South Korea Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.5.2. Key Country Dynamics
      • 8.4.5.3. Regulatory Framework
      • 8.4.5.4. Competitive Scenario
    • 8.4.6. Australia
      • 8.4.6.1. Australia Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.6.2. Key Country Dynamics
      • 8.4.6.3. Regulatory Framework
      • 8.4.6.4. Competitive Scenario
    • 8.4.7. Thailand
      • 8.4.7.1. Thailand Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.7.2. Key Country Dynamics
      • 8.4.7.3. Regulatory Framework
      • 8.4.7.4. Competitive Scenario
  • 8.5. Latin America
    • 8.5.1. Latin America Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.5.2. Key Country Dynamics
    • 8.5.3. Regulatory Framework
    • 8.5.4. Competitive Scenario
    • 8.5.5. Brazil
      • 8.5.5.1. Brazil Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.5.5.2. Key Country Dynamics
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Competitive Scenario
    • 8.5.6. Argentina
      • 8.5.6.1. Argentina Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.5.6.2. Key Country Dynamics
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Competitive Scenario
  • 8.6. MEA
    • 8.6.1. MEA Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. South Africa Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.6.2.2. Key Country Dynamics
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Competitive Scenario
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Saudi Arabia Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.6.3.2. Key Country Dynamics
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Competitive Scenario
    • 8.6.4. UAE
      • 8.6.4.1. UAE Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.6.4.2. Key Country Dynamics
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Competitive Scenario
    • 8.6.5. Kuwait
      • 8.6.5.1. Kuwait Breast Cancer Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.6.5.2. Key Country Dynamics
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Competitive Scenario

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Strategy Mapping
    • 9.2.1. Acquisition
    • 9.2.2. Collaborations
    • 9.2.3. New Platform Launches
    • 9.2.4. Others
  • 9.3. Company Profiles/Listing
    • 9.3.1. Hologic Inc.
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Platform Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Genomic Health (Exact Sciences Corporation)
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Platform Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. BD
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Platform Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. Danaher
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Platform Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. Koninklijke Philips N.V
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Platform Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. QIAGEN
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Platform Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. Thermo Fisher Scientific Inc
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Platform Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. Myriad Genetics
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Platform Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. Argon Medical Devices, Inc.
      • 9.3.9.1. Company Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Platform Benchmarking
      • 9.3.9.4. Strategic Initiatives
    • 9.3.10. F. Hoffmann-La Roche Ltd.
      • 9.3.10.1. Company Overview
      • 9.3.10.2. Financial Performance
      • 9.3.10.3. Platform Benchmarking
      • 9.3.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 4 Global Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 5 Global Breast Cancer Diagnostics Market, by Application, 2021 - 2033 (USD Million)
  • Table 6 Global Breast Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Million)
  • Table 7 Global Breast Cancer Diagnostics Market, by Region, 2021 - 2033 (USD Million)
  • Table 8 North America Breast Cancer Diagnostics Market, by Country, 2021 - 2033 (USD Million)
  • Table 9 North America Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 10 North America Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 11 North America Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 12 North America OTC U.S. Breast Cancer Diagnostics Market, by End Use, 2021 - 2033 (USD Million)
  • Table 13 U.S. Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 14 U.S. Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 15 U.S. Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 16 U.S. Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 17 Canada Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 18 Canada Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 19 Canada Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 20 Canada Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 21 Mexico Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 22 Mexico Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 23 Mexico Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 24 Mexico Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 25 Europe Breast Cancer Diagnostics Market, by Country, 2021 - 2033 (USD Million)
  • Table 26 Europe Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 27 Europe Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 28 Europe Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 29 Europe Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 30 UK Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 31 UK Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 32 UK Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 33 UK Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 34 Germany Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 35 Germany Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 36 Germany Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 37 Germany Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 38 France Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 39 France Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 40 France Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 41 France Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 42 Italy Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 43 Italy Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 44 Italy Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 45 Italy Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 46 Spain Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 47 Spain Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 48 Spain Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 49 Spain Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 50 Norway Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 51 Norway Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 52 Norway Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 53 Norway Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 54 Sweden Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 55 Sweden Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 56 Sweden Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 57 Sweden Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 58 Denmark Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 59 Denmark Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 60 Denmark Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 61 Denmark Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 62 Asia Pacific Breast Cancer Diagnostics Market, by Country, 2021 - 2033 (USD Million)
  • Table 63 Asia Pacific Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 64 Asia Pacific Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 65 Asia Pacific Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 66 Asia Pacific Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 67 Japan Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 68 Japan Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 69 Japan Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 70 Japan Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 71 China Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 72 China Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 73 China Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 74 China Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 75 India Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 76 India Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 77 India Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 78 India Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 79 Australia Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 80 Australia Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 81 Australia Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 82 Australia Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 83 South Korea Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 84 South Korea Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 85 South Korea Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 86 South Korea Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 87 Thailand Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 88 Thailand Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 89 Thailand Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 90 Thailand Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 91 Latin America Breast Cancer Diagnostics Market, by Country, 2021 - 2033 (USD Million)
  • Table 92 Latin America Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 93 Latin America Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 94 Latin America Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 95 Latin America Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 96 Brazil Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 97 Brazil Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 98 Brazil Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 99 Brazil Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 100 Argentina Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 101 Argentina Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 102 Argentina Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 103 Argentina Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 104 Middle East Africa Breast Cancer Diagnostics Market, by Country, 2021 - 2033 (USD Million)
  • Table 105 Middle East Africa Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 106 Middle East Africa Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 107 Middle East Africa Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 108 Middle East Africa Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 109 South Africa Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 110 South Africa Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 111 South Africa Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 112 South Africa Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 113 Saudi Arabia Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 114 Saudi Arabia Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 115 Saudi Arabia Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 116 Saudi Arabia Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 117 UAE Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 118 UAE Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 119 UAE Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 120 UAE Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)
  • Table 121 Kuwait Breast Cancer Diagnostics Market, by Type, 2021 - 2033 (USD Million)
  • Table 122 Kuwait Breast Cancer Diagnostics Market, by Product, 2021 - 2033 (USD Million)
  • Table 123 Kuwait Breast Cancer Diagnostics Market by Application, 2021 - 2033 (USD Million)
  • Table 124 Kuwait Breast Cancer Diagnostics Market by End Use, 2021 - 2033 (USD Million)

List of Figures

  • FIG. 1 Market Research Process
  • FIG. 2 Information Procurement
  • FIG. 3 Primary Research Pattern
  • FIG. 4 Market Research Approaches
  • FIG. 5 Value Chain-Based Sizing & Forecasting
  • FIG. 6 Market Formulation & Validation
  • FIG. 7 Market Segmentation
  • FIG. 8 Market Snapshot, 2025
  • FIG. 9 Market Trends & Outlook
  • FIG. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • FIG. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • FIG. 12 SWOT Analysis, By Factor (Political & Legal, Economic, And Technological)
  • FIG. 13 Porter's Five Forces Analysis
  • FIG. 14 Market Penetration & Growth Prospect Mapping, 2025
  • FIG. 15 Global Breast Cancer Diagnostics Market: Type Movement Analysis
  • FIG. 16 Global Imaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 17 Global Biopsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 18 Global Genomic Tests Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 19 Global Blood Tests Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 20 Global Other Tests Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 21 Global Breast Cancer Diagnostics Market: Product Movement Analysis
  • FIG. 22 Global Platform-Based Products Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 23 Global Imaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 24 Global Biopsy Products Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 25 Global Instrument-Based Products Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 26 Global Microarrays Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 27 Global PCR Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 28 Global Next Generation Sequencing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 29 Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 30 Global Breast Cancer Diagnostics Market: Application Movement Analysis
  • FIG. 31 Global Screening Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 32 Global Diagnostic & Predictive Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 33 Global Prognostic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 34 Global Research Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 35 Global Breast Cancer Diagnostics Market: End-Use Movement Analysis
  • FIG. 36 Global Hospitals & Clinics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 37 Global Medical Labs & Diagnostics Centres Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 38 Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 39 Regional Marketplace: Key Takeaways
  • FIG. 40 Regional Outlook, 2025 & 2033
  • FIG. 41 Global Breast Cancer Diagnostics Market: Regional Movement Analysis
  • FIG. 42 North America Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 43 U.S. Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 44 Canada Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 45 Mexico Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 46 Europe Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 47 Germany Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 48 UK Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 49 France Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 50 Italy Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 51 Spain Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 52 Denmark Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 53 Sweden Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 54 Norway Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 55 Asia Pacific Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 56 Japan Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 57 China Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 58 India Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 59 Australia Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 60 South Korea Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 61 Thailand Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 62 Latin America Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 63 Brazil Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 64 Argentina Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 65 Middle East And Africa Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 66 South Africa Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 67 Saudi Arabia Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 68 UAE Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • FIG. 69 Kuwait Breast Cancer Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)